Aging Clocks: What They Actually Measure (And Why Most Are Still Wrong)
Not all biological age clocks are equal. Learn why third-generation clocks like DunedinPACE outperform Horvath by orders of magnitude — and what to demand before paying for a test.
Longevity Quotient: When a Clinical Score Meets Continuous Wearable Data
Agentis Longevity integrates Ultrahuman's Ring AIR and M1 CGM into its Longevity Quotient — giving a five-component clinical score a real-time wearable data layer.
Ultrahuman Wearables Now Power a Living Longevity Score
Agentis and Ultrahuman link real-time ring and CGM data to the Longevity Quotient — a living composite score that tracks where your health trajectory is heading.
Magnesium Forms: Why the Type You Take Changes Everything
80% of people are magnesium deficient, but most supplements use a form with 4% bioavailability. Here's which form works for sleep, cognition, and energy.
Cataracts and Dementia Risk: The Surprisingly Simple Brain-Protection Lever
A meta-analysis of 558,276 participants finds cataract surgery associated with 25% lower dementia risk. Vision correction may be one of the most accessible cognitive interventions in aging.
Portable Red Light Therapy Devices in 2026: A Tiered Buyer's Guide
The home RLT market hit $1.2B and is growing at 59% annually. What the numbers don't show: major capability gaps between $295 portable panels and $549 wearable devices.
Peter Attia AMA #82: From Longevity Theory to Real-World Practice
AMA #82 shifts from mechanism to application — DEXA interpretation, wearables use, stability training, and the habits that actually stick for patients in their 40s through 60s.
NLRP3: The Inflammasome Switch Linking Aging to Chronic Disease
NLRP3 links obesity, Alzheimer's, and aging through a single inflammasome. Suppressing it extended mouse lifespan 34%. Q2 2026 clinical trial data is due.
VITAL-H: The $38M Trial Testing Rapamycin, Ozempic, and Farxiga Against Aging
A federally funded trial at UT Health San Antonio is testing three FDA-approved drugs in 726 healthy adults aged 60–65 to see if aging itself can be slowed with existing medications.
ZEUGMA Hyperbaric Chamber: When HBOT Becomes a Longevity Engineering Tool
HPO.TECH's ZEUGMA chamber takes hyperbaric oxygen therapy from clinical setting to performance optimization — dissolving oxygen directly into plasma at 2.4 ATA for recovery and longevity.
Your Smartwatch May Be Able to Predict Cognitive Decline — Before You Notice It
A University of Geneva study using 88 participants over 10 months found AI can predict fluctuations in brain health from passive wearable data with just 12.5% average error.
Obicetrapib: The Drug Targeting Both Heart Disease and Alzheimer's at Once
A CETP inhibitor in late-stage trials cut LDL by up to 50% while reducing Alzheimer's biomarkers. The BROADWAY trial data may represent a new category of longevity drug.
One Man's Alzheimer's Mutation Isn't Causing Dementia. Heat Shock Proteins May Be Why.
A 75-year-old with a dominant Alzheimer's mutation remains cognitively healthy. Heat shock proteins may explain why — and what it means for brain longevity research.
Mimio: The Fasting Mimetic With a Peer-Reviewed RCT Behind It
Mimio's randomized placebo-controlled trial in Nature Scientific Reports shows reduced LDL, fasting glucose, and oxidized LDL in 8 weeks — without dietary changes or actual fasting.
Sleep: Top Health Priority, Lowest Follow-Through
ResMed surveyed 30,000 people across 13 countries: 84% know sleep extends healthy lifespan, but 53% get quality sleep only 4 nights a week. Wearable tracking tripled in one year.
Peter Attia's AMA 81: Biological Age Tests, GLP-1s, and What Actually Moves the Needle
AMA 81 covers biological age clocks, GLP-1 receptor agonists, Zone 2 training, and sun exposure — a distillation of what biohacking evidence says is worth acting on in 2026.
Why Your Biohacking Stack Isn't Working: The Context Problem
The reason most health interventions fail isn't the intervention — it's the absence of a personalized model of how your biology actually responds.
GRAIL's Trial Missed Its Endpoint. That's Not the Same as Failing.
Peter Attia's analysis of GRAIL's landmark cancer screening trial: a missed composite endpoint doesn't tell you whether multi-cancer early detection technology works.
NR Sales Hit $129M: What Niagen Bioscience's 30% Growth Signals About the NAD+ Market
Niagen Bioscience reported $129.4M in 2025 revenue — up 30% — with net income more than doubling. The NAD+ precursor category is no longer a niche bet.
The Near-Future Biohacking Platform: Eight Sleep's Path to Preventive Healthcare
With a $1.5B valuation and the new Pod 5 architecture, Eight Sleep is transitioning from a smart mattress to a comprehensive preventive health stack.
Sensory Stimulation Architecture: Cognito's $105M Cognitive Longevity Play
Cognito Therapeutics secures $105M to advance its non-invasive sensory stimulation therapy, marking a shift in Alzheimer's treatment architecture from chemical to electrical intervention.
The Architecture of Continuous Biosensing: From Wearables to Woven Systems
Analyzing the 2026 shift toward multi-sensor biosensing platforms and the quantification of aging through the ARPA-H and WHOOP initiative.
Gamma-Band Modulation: The Hardware-Software Convergence in Cognitive Longevity
Analyzing the Spectris platform's use of sensory-driven gamma oscillations to preserve neural architecture and cognitive function.
Oura Ring 4 vs Eight Sleep Pod 5: The Recovery Architecture Duel
A technical comparison of wearable versus environmental recovery systems for high-performance human architecture.